» Articles » PMID: 20028517

CXCR4 Expression Heterogeneity in Neuroblastoma Cells Due to Ligand-independent Regulation

Overview
Journal Mol Cancer
Publisher Biomed Central
Date 2009 Dec 24
PMID 20028517
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Background: CXCR4, the receptor for the chemokine stromal-derived factor 1 (SDF-1), has been shown to mediate many of the processes essential for cancer progression such as tumor cell proliferation, metastasis, and angiogenesis. To understand the role of CXCR4 in the biology of neuroblastoma, a disease that presents with wide spread metastases in over 50% of patients, we screened ten patient derived-neuroblastoma cell-lines for basal CXCR4 expression and sought to identify characteristics that correlate with tumor cell phenotype.

Results: All cell lines expressed CXCR4 mRNA at variable levels, that correlated well with three distinct classes of CXCR4 surface expression (low, moderate, or high) as defined by flow cytometry. Analysis of the kinetics of CXCR4 surface expression on moderate and high expressing cell lines showed a time-dependent down-regulation of the receptor that directly correlated with cell confluency, and was independent of SDF1. Cell lysates showed the presence of multiple CXCR4 isoforms with three major species of approximately 87, 67 and 55 kDa associating with high surface expression, and two distinct species of 45 and 38 kDa correlating with low to null surface expression. Western blot analysis of CXCR4 immunoprecipitates showed that the 87 and 67 kDa forms were ubiquitinated, while the others were not. Finally, treatment of cells with a proteasome inhibitor resulted in down regulation of CXCR4 surface expression.

Conclusions: Taken together, these data show that regulation of CXCR4 surface expression in neuroblastoma cells can occur independently of SDF-1 contribution arguing against an autocrine mechanism. Additionally these data suggest that post-translational modifications of CXCR4, in part through direct ubiquitination, can influence trafficking of CXCR4 to the surface of neuroblastoma cells in a ligand-independent manner.

Citing Articles

MIF/CXCR4 signaling axis contributes to survival, invasion, and drug resistance of metastatic neuroblastoma cells in the bone marrow microenvironment.

Garcia-Gerique L, Garcia M, Garrido-Garcia A, Gomez-Gonzalez S, Torrebadell M, Prada E BMC Cancer. 2022; 22(1):669.

PMID: 35715791 PMC: 9206243. DOI: 10.1186/s12885-022-09725-8.


Targeting the Tumor Microenvironment in Neuroblastoma: Recent Advances and Future Directions.

Joshi S Cancers (Basel). 2020; 12(8).

PMID: 32722460 PMC: 7465822. DOI: 10.3390/cancers12082057.


The CXCR4 antagonist plerixafor (AMD3100) promotes proliferation of Ewing sarcoma cell lines in vitro and activates receptor tyrosine kinase signaling.

Berning P, Schaefer C, Clemens D, Korsching E, Dirksen U, Potratz J Cell Commun Signal. 2018; 16(1):21.

PMID: 29776413 PMC: 5960216. DOI: 10.1186/s12964-018-0233-2.


CXCR4: A new player in vestibular schwannoma pathogenesis.

Breun M, Schwerdtfeger A, Martellotta D, Kessler A, Perez J, Monoranu C Oncotarget. 2018; 9(11):9940-9950.

PMID: 29515781 PMC: 5839412. DOI: 10.18632/oncotarget.24119.


Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study.

Salgia R, Weaver R, McCleod M, Stille J, Yan S, Roberson S Invest New Drugs. 2017; 35(3):334-344.

PMID: 28299514 PMC: 5418321. DOI: 10.1007/s10637-017-0446-z.


References
1.
Geminder H, Sagi-Assif O, Goldberg L, Meshel T, Rechavi G, Witz I . A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma. J Immunol. 2001; 167(8):4747-57. DOI: 10.4049/jimmunol.167.8.4747. View

2.
Balkwill F . The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol. 2004; 14(3):171-9. DOI: 10.1016/j.semcancer.2003.10.003. View

3.
Hernandez P, Gorlin R, Lukens J, Taniuchi S, Bohinjec J, Francois F . Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease. Nat Genet. 2003; 34(1):70-4. DOI: 10.1038/ng1149. View

4.
Marchese A, Raiborg C, Santini F, Keen J, Stenmark H, Benovic J . The E3 ubiquitin ligase AIP4 mediates ubiquitination and sorting of the G protein-coupled receptor CXCR4. Dev Cell. 2003; 5(5):709-22. DOI: 10.1016/s1534-5807(03)00321-6. View

5.
Luker K, Luker G . Functions of CXCL12 and CXCR4 in breast cancer. Cancer Lett. 2005; 238(1):30-41. DOI: 10.1016/j.canlet.2005.06.021. View